LY2409021

DRUG15 trials

Sponsors

Eli Lilly and Company, University Hospital, Gentofte, Copenhagen

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HealthyHealthy ParticipantsHealthy VolunteersKidney Failure, ChronicRenal Insufficiency, ChronicType 2 Diabetes

Phase 1

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

CompletedNCT01460368

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2011-10-31End: 2012-03-31Updated: 2019-01-07

The Effects of LY2409021 on the Liver

CompletedNCT01588366

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2012-04-30End: 2013-09-30Updated: 2019-03-07

A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes

CompletedNCT01606371

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2007-05-31End: 2007-10-31Updated: 2012-05-25

A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes

CompletedNCT01606397

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2008-03-31End: 2008-11-30Updated: 2012-05-25

The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants

CompletedNCT01606423

Eli Lilly and CompanyHealthy Volunteers

Start: 2007-11-30End: 2008-03-31Updated: 2012-05-25

Study of LY2409021 in Participants With Type 1 Diabetes

CompletedNCT01640834

Eli Lilly and CompanyDiabetes Mellitus, Type 1

Start: 2012-07-31End: 2012-09-30Updated: 2018-10-29

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

CompletedNCT01836198

Eli Lilly and CompanyHealthy Volunteers

Start: 2013-05-31End: 2013-11-30Updated: 2019-03-08

A Study of LY2409021 in Participants With Different Levels of Kidney Function

CompletedNCT01929109

Eli Lilly and CompanyKidney Failure, Chronic, Renal Insufficiency, Chronic

Start: 2013-08-31End: 2014-08-31Updated: 2018-10-29

A Study of LY2409021 in Healthy Participants

CompletedNCT02217618

Eli Lilly and CompanyHealthy Participants

Start: 2014-08-31End: 2014-09-30Updated: 2018-10-29

A Study of LY2409021 Formulations in Healthy Participants

TerminatedNCT02385084

Eli Lilly and CompanyHealthy

Start: 2015-03-31End: 2015-05-31Updated: 2018-10-29

Phase 2

A Study for Participants With Type 2 Diabetes Mellitus

CompletedNCT00871572

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2009-03-31End: 2010-02-28Updated: 2018-04-24

A Study of LY2409021 in Patients With Type 2 Diabetes

CompletedNCT01241448

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2011-01-31End: 2012-03-31Updated: 2018-04-24

A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus

CompletedNCT02091362

Eli Lilly and CompanyType 2 Diabetes Mellitus

Start: 2014-03-31End: 2015-01-31Updated: 2018-07-19

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

TerminatedNCT02111096

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2014-04-30End: 2015-09-30Updated: 2019-10-09

Unknown Phase

Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes

CompletedNCT02669524

University Hospital, Gentofte, CopenhagenType 2 Diabetes

Start: 2015-10-31End: 2016-08-31Updated: 2016-10-25